Speaker illustration

Doctor Qidi Ying

Ningbo NO2 Hospital, Ningbo (China)

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

Event: ESC Congress 2021 - The Digital Experience

Topic: Lipid-Lowering Agents

Session: Congress committee e-posters choice in pharmacology and pharmacotherapy

Thumbnail